BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hill QA, Owen RG. CNS prophylaxis in lymphoma: Who to target and what therapy to use. Blood Reviews 2006;20:319-32. [DOI: 10.1016/j.blre.2006.02.001] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Della Rocca AM, Tonin FS, Fachi MM, Cobre AF, Ferreira VL, Leonart LP, Steffenello-Durigon G, Del Moral JAG, Lenzi L, Pontarolo R. Prognostic Factors, Survival Analyses and the Risk of Second Primary Cancer: A Population-Based Study on Burkitt Lymphoma/Leukemia. Diseases 2021;9:43. [PMID: 34203748 DOI: 10.3390/diseases9020043] [Reference Citation Analysis]
2 Di Noto R, Scalia G, Abate G, Gorrese M, Pascariello C, Raia M, Morabito P, Capone F, Pardo CL, Mirabelli P, Mariotti E, Del Vecchio L. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leukemia Research 2008;32:1196-9. [DOI: 10.1016/j.leukres.2007.12.016] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
3 Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008;49:1745-51. [PMID: 18798109 DOI: 10.1080/10428190802226425] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 5.5] [Reference Citation Analysis]
4 Chuang S, Huang W, Hsieh P, Jung Y, Ye H, Du M, Lu C, Cho C, Hsiao S, Hsu Y, Lin K. Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology 2008;52:427-35. [DOI: 10.1111/j.1365-2559.2008.02974.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
5 Ghose A, Kundu R, Latif T. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma. Critical Reviews in Oncology/Hematology 2014;91:292-303. [DOI: 10.1016/j.critrevonc.2014.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, Neuwelt EA. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007;25:2295-305. [PMID: 17538176 DOI: 10.1200/JCO.2006.09.9861] [Cited by in Crossref: 282] [Cited by in F6Publishing: 138] [Article Influence: 18.8] [Reference Citation Analysis]
7 Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 2009;36:S2-S16. [PMID: 19660680 DOI: 10.1053/j.seminoncol.2009.05.002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 81] [Article Influence: 7.2] [Reference Citation Analysis]
8 Cesana C, Klersy C, Scarpati B, Brando B, Faleri M, Bertani G, Gatti A, Volpato E, Barba C, Ferri U, Scampini L, Grillo G, Lando G, Nosari A, Morra E, Cairoli R. Flow cytometry and cytomorphology evaluation of hematologic malignancy in cerebrospinal fluids: comparison with retrospective clinical outcome. Ann Hematol 2011;90:827-35. [PMID: 21212952 DOI: 10.1007/s00277-010-1145-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
9 Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol 2016;97:108-20. [PMID: 27096423 DOI: 10.1111/ejh.12763] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
10 Sasaki M, Sugimoto K, Masuda A, Tsukune Y, Yahata Y, Komatsu N. Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapy. J Neurooncol 2010;99:295-6. [DOI: 10.1007/s11060-010-0132-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Haaxma-Reiche H. Neurological complications of leukemia and lymphoma. Handb Clin Neurol 2012;105:711-29. [PMID: 22230529 DOI: 10.1016/B978-0-444-53502-3.00019-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Mitobe M, Kawamoto K, Suzuki T, Suwabe T, Shibasaki Y, Masuko M, Inoue K, Miyoshi H, Ohshima K, Sone H, Takizawa J. DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction. J Clin Exp Hematop 2021;61:42-7. [PMID: 33551436 DOI: 10.3960/jslrt.20043] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sou R, Ohguro N, Maeda T, Saishin Y, Tano Y. Treatment of primary intraocular lymphoma with intravitreal methotrexate. Jpn J Ophthalmol 2008;52:167-74. [PMID: 18661266 DOI: 10.1007/s10384-008-0519-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
14 Hashida N, Nakai K, Saitoh N, Nishida K. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol 2014;252:687-93. [DOI: 10.1007/s00417-014-2584-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
15 Meng X, Yu J, Fan Q, Li L, Li W, Song Z, Liu X, Jiang Y, Gao M, Zhang H. Characteristics and outcomes of non-Hodgkin's lymphoma patients with leptomeningeal metastases. Int J Clin Oncol 2018;23:783-9. [PMID: 29558001 DOI: 10.1007/s10147-018-1268-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Liu X, Mo F, Zeng H, Zhu S, Ma X. Quantitative proteomic analysis of cerebrospinal fluid from patients with diffuse large B-cell lymphoma with central nervous system involvement: A novel approach to diagnosis. Biomed Rep 2019;11:70-8. [PMID: 31338193 DOI: 10.3892/br.2019.1222] [Reference Citation Analysis]
17 Kwong YL, Yeung DY, Chan JC. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 2009;88:193-201. [PMID: 19050889 DOI: 10.1007/s00277-008-0645-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
18 Jiang W, Yang Y, Mercer-Smith AR, Valdivia A, Bago JR, Woodell AS, Buckley AA, Marand MH, Qian L, Anders CK, Hingtgen SD. Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers. Sci Adv 2021;7:eabf1526. [PMID: 34108203 DOI: 10.1126/sciadv.abf1526] [Reference Citation Analysis]
19 Akkas BE, Vural GU. The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT. Nucl Med Commun 2013;34:50-6. [PMID: 23111376 DOI: 10.1097/MNM.0b013e32835aaa48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol 2013;24:2236-44. [PMID: 23712546 DOI: 10.1093/annonc/mdt192] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
21 Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, De Chiara A, Morelli E, Capobianco G, Becchimanzi C, Volzone F, Saggese M, Marcacci G, De Filippi R, Vitolo U, Pinto A. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma: RD-CODOX-M/IVAC in adult BL and BL/DLBCL. British Journal of Haematology 2012;156:234-44. [DOI: 10.1111/j.1365-2141.2011.08947.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
22 Van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leukemia & Lymphoma 2009;49:52-8. [DOI: 10.1080/10428190802311458] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
23 Zheng W, Zhang G, Tan C, Shen J, Yang J, Zhong H. Diabetes insipidus as main presentation of non-Hodgkin's lymphoma with hypophyseal involvement: Two case reports. Leukemia Research 2010;34:e32-4. [DOI: 10.1016/j.leukres.2009.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Wang Y, Wang C, Sun P, Liu P, Yang H, Wang H, Rao H, Li S, Jiang W, Huang J, Li Z. Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination. Front Oncol 2022;12:796738. [DOI: 10.3389/fonc.2022.796738] [Reference Citation Analysis]
25 Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2008;111:1085-93. [DOI: 10.1182/blood-2007-07-101402] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
26 Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom? Blood Reviews 2012;26:97-106. [DOI: 10.1016/j.blre.2011.12.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
27 Sancho J, Morgades M, Alonso N, Deben G, de Sevilla AF, Vázquez L, Nicolás C, García Vela J, Arranz R, Abella E, Canales M, Miralles P, Sánchez E, Hermosilla M, Conde E, Rueda A, Ribera J. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin’s lymphoma in Spain. Medicina Clínica 2008;131:441-6. [DOI: 10.1157/13126952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
28 Lee K, Yoon DH, Hong JY, Kim S, Lee K, Kang EH, Huh J, Park CS, Lee SW, Suh C. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. Int J Hematol 2019;110:86-94. [PMID: 31115880 DOI: 10.1007/s12185-019-02653-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
29 Malikova H, Burghardtova M, Koubska E, Mandys V, Kozak T, Weichet J. Secondary central nervous system lymphoma: spectrum of morphological MRI appearances. Neuropsychiatr Dis Treat 2018;14:733-40. [PMID: 29559780 DOI: 10.2147/NDT.S157959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
30 Shin SY, Lee ST, Kim HJ, Oh YL, Kim SJ, Kim WS, Kim SH. Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. Ann Lab Med 2016;36:209-14. [PMID: 26915608 DOI: 10.3343/alm.2016.36.3.209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, Tirumani SH. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging 2019;10:56. [PMID: 31115699 DOI: 10.1186/s13244-019-0733-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
32 Grinberg I, Reis A, Ohana A, Taizi M, Cipok M, Tavor S, Rund D, Deutsch VR, Goldstein RS. Engraftment of human blood malignancies to the turkey embryo: a robust new in vivo model. Leuk Res 2009;33:1417-26. [PMID: 19297019 DOI: 10.1016/j.leukres.2009.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
33 Lasocki A, Seymour J. Central nervous system manifestations of systemic haematological malignancies and key differentials. Clinical Radiology 2022. [DOI: 10.1016/j.crad.2022.01.043] [Reference Citation Analysis]
34 Nabavizadeh SA, Vossough A, Hajmomenian M, Assadsangabi R, Mohan S. Neuroimaging in Central Nervous System Lymphoma. Hematol Oncol Clin North Am. 2016;30:799-821. [PMID: 27443998 DOI: 10.1016/j.hoc.2016.03.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
35 Song YS, Lee WW, Lee JS, Kim SE. Prediction of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Using Pretherapeutic [18F]2-Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography/Computed Tomography. Medicine (Baltimore) 2015;94:e1978. [PMID: 26554808 DOI: 10.1097/MD.0000000000001978] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lin Y, Pan YH, Li MK, Zong XD, Pan XM, Tan SY, Guo YW. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report. World J Gastroenterol 2021; 27(45): 7844-7854 [PMID: 34963746 DOI: 10.3748/wjg.v27.i45.7844] [Reference Citation Analysis]
37 Miralles P, Navarro JT, Berenguer J, Gómez Codina J, Kwon M, Serrano D, Díez-Martín JL, Villà S, Rubio R, Menárguez J, Ribera Santasusana JM. GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. Med Clin (Barc) 2018;151:39.e1-39.e17. [PMID: 29357988 DOI: 10.1016/j.medcli.2017.11.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Murata Y, Hata Y, Noda Y, Matsusaka S, Fukui N, Kadota T, Iwata J, Machida T, Yamagami T. Secondary central nervous system lymphoma surrounding a region injured by subarachnoid hemorrhage and subsequent aneurysmal clipping. Biomed Rep 2017;7:474-6. [PMID: 29181160 DOI: 10.3892/br.2017.981] [Reference Citation Analysis]
39 Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Science 2012;103:245-51. [DOI: 10.1111/j.1349-7006.2011.02139.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 5.4] [Reference Citation Analysis]
40 Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood 2021;137:743-50. [PMID: 33171490 DOI: 10.1182/blood.2019004099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009;89:577-83. [PMID: 19353238 DOI: 10.1007/s12185-009-0289-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
42 Cheah CY, Seymour JF. Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When? Curr Oncol Rep 2015;17. [DOI: 10.1007/s11912-015-0450-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
43 Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leukemia & Lymphoma 2011;52:2270-5. [DOI: 10.3109/10428194.2011.596966] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
44 Ahluwalia MS, Wallace PK, Peereboom DM. Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis: Ready for prime time? Cancer 2012;118:1747-53. [DOI: 10.1002/cncr.26335] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
45 Avilés A, Jesús Nambo M, Neri N. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol 2013;30:520. [PMID: 23456620 DOI: 10.1007/s12032-013-0520-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
46 Kridel R, Dietrich P. Prevention of CNS relapse in diffuse large B-cell lymphoma. The Lancet Oncology 2011;12:1258-66. [DOI: 10.1016/s1470-2045(11)70140-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
47 Avivi I, Farbstein D, Brenner B, Horowitz NA. Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. Blood Rev. 2014;28:213-220. [PMID: 25108745 DOI: 10.1016/j.blre.2014.06.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
48 Lambe G, Doran S, Clifford R, Nasoodi A. Isolated CNS relapse of medullary aggressive high-grade B-cell lymphoma on 18F-FDG-PET/CT. Eur J Hybrid Imaging 2022;6:9. [PMID: 35501493 DOI: 10.1186/s41824-022-00130-9] [Reference Citation Analysis]
49 Bobillo S, Abrisqueta P, Carpio C, Raheja P, Castellví J, Crespo M, Bosch F. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica 2018;103:e92-3. [PMID: 29242296 DOI: 10.3324/haematol.2017.181636] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
50 Canova F, Marino D, Trentin C, Soldà C, Ghiotto C, Aversa SML. Intrathecal chemotherapy in lymphomatous meningitis. Critical Reviews in Oncology/Hematology 2011;79:127-34. [DOI: 10.1016/j.critrevonc.2010.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
51 Hematology Oncology Committee, Chinese Anti- Cancer Association; Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia(2016)]. Zhonghua Xue Ye Xue Za Zhi 2016;37:837-45. [PMID: 27801310 DOI: 10.3760/cma.j.issn.0253-2727.2016.10.002] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
52 Stefoni V, Broccoli A, Pellegrini C, Derenzini E, Fina M, Zinzani PL. CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. J Neurooncol 2009;95:135-9. [PMID: 19381440 DOI: 10.1007/s11060-009-9898-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
53 Jahnke K, Thiel E. Treatment options for central nervous system lymphomas in immunocompetent patients. Expert Review of Neurotherapeutics 2014;9:1497-509. [DOI: 10.1586/ern.09.100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
54 Korfel A, Schlegel U, Johnson DR, Kaufmann TJ, Giannini C, Hirose T. Case-based review: primary central nervous system lymphoma. Neurooncol Pract 2017;4:46-59. [PMID: 31386044 DOI: 10.1093/nop/npw033] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Herr MM, Mohile NA, van Wijngaarden E, Brown EB, Rich DQ. Antidepressant use and risk of central nervous system metastasis. J Neurooncol 2016;129:179-87. [DOI: 10.1007/s11060-016-2165-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
56 Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 2010;116:2290-300. [PMID: 20209620 DOI: 10.1002/cncr.25008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 23] [Article Influence: 0.3] [Reference Citation Analysis]
57 Villa D, Connors J, Shenkier T, Gascoyne R, Sehn L, Savage K. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology 2010;21:1046-52. [DOI: 10.1093/annonc/mdp432] [Cited by in Crossref: 130] [Cited by in F6Publishing: 121] [Article Influence: 10.8] [Reference Citation Analysis]
58 Verdu-Bou M, Tapia G, Hernandez-Rodriguez A, Navarro JT. Clinical and Therapeutic Implications of Epstein-Barr Virus in HIV-Related Lymphomas. Cancers (Basel) 2021;13:5534. [PMID: 34771697 DOI: 10.3390/cancers13215534] [Reference Citation Analysis]
59 Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F. Should Intra-cerebrospinal Fluid Prophylaxis Be Part of Initial Therapy for Patients With Non-Hodgkin Lymphoma: What We Know, and How We Can Find Out More. Seminars in Oncology 2009;36:S25-34. [DOI: 10.1053/j.seminoncol.2009.05.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
60 Ganjoo K, Advani R, Mariappan MR, Mcmillan A, Horning S. Non-Hodgkin lymphoma of the breast. Cancer 2007;110:25-30. [DOI: 10.1002/cncr.22753] [Cited by in Crossref: 78] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
61 Thomas LC, Adonizio C, Filicko-o'hara J, Golshayan AR, Costa LJ, Morris GJ. Testicular Lymphoma. Seminars in Oncology 2010;37:549-54. [DOI: 10.1053/j.seminoncol.2010.10.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
62 Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, Moskowitz C, Hamlin P, Horwitz S. Central nervous system involvement in T-cell lymphoma: A single center experience. Acta Oncol 2016;55:561-6. [PMID: 27046135 DOI: 10.3109/0284186X.2015.1118656] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
63 Validire P, Capovilla M, Asselain B, Kirova Y, Goudefroye R, Plancher C, Fourquet A, Zanni M, Gaulard P, Vincent-Salomon A, Decaudin D. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol 2009;84:133-9. [PMID: 19199367 DOI: 10.1002/ajh.21353] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
64 Lee K, Yi J, Choi IS, Kim JH, Bang S, Kim D, Im S, Kim T, Yoon S, Lee JS, Bang Y, Park S, Kim BK, Cho HI, Heo DS. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. Ann Hematol 2009;88:829-38. [DOI: 10.1007/s00277-008-0682-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
65 Petković I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn) 2015;19:428-35. [PMID: 26843837 DOI: 10.5114/wo.2015.56388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
66 Sayed D, Badrawy H, Ali AM, Shaker S. Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia. Leuk Res 2009;33:655-61. [PMID: 18996593 DOI: 10.1016/j.leukres.2008.09.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
67 Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis M, Kotsianidis I, Kalpadakis C, Dimopoulos M, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab: CNS relapses after R-CHOP in primary mediastinal large B-cell lymphoma. Hematol Oncol 2013;31:10-7. [DOI: 10.1002/hon.2012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
68 Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 2014;55:509-14. [PMID: 23741977 DOI: 10.3109/10428194.2013.811239] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
69 Keraliya AR, Krajewski KM, Giardino AA, Tirumani SH, Shinagare AB, Ramaiya NH, Jagannathan JP. Imaging of Nervous System Involvement in Hematologic Malignancies: What Radiologists Need to Know. American Journal of Roentgenology 2015;205:604-17. [DOI: 10.2214/ajr.14.14092] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
70 Talybov R, Beylerli O, Mochalov V, Prokopenko A, Ilyasova T, Trofimova T, Sufianov A, Guang Y. Multiparametric MR Imaging Features of Primary CNS Lymphomas. Front Surg 2022;9:887249. [DOI: 10.3389/fsurg.2022.887249] [Reference Citation Analysis]
71 Cheah CY, Seymour JF, Dickinson M. Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma. International Journal of Hematologic Oncology 2014;3:189-201. [DOI: 10.2217/ijh.14.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, McMillan A. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011;153:451-485. [PMID: 21480860 DOI: 10.1111/j.1365-2141.2011.08651.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
73 Chukwueke UN, Nayak L. Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America 2019;33:597-611. [DOI: 10.1016/j.hoc.2019.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
74 Lask A, Ophir E, Or-Geva N, Cohen-Fredarow A, Afik R, Eidelstein Y, Reich-Zeliger S, Nathansohn B, Edinger M, Negrin RS, Hagin D, Reisner Y. A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells. Blood 2013;121:3033-40. [PMID: 23446736 DOI: 10.1182/blood-2012-06-432443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ. Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era. Clin Lymphoma Myeloma Leuk 2016;16:e123-7. [PMID: 27375157 DOI: 10.1016/j.clml.2016.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
76 Kasparian S, Burns E, Shehabeldin A, Awar M, Pingali SR. Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: a case report and review of the literature. J Med Case Rep 2020;14:127. [PMID: 32782017 DOI: 10.1186/s13256-020-02449-y] [Reference Citation Analysis]
77 Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, Kim K, Kim SJ, Ko YH, Kim WS. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol 2011;22:1636-43. [PMID: 21220520 DOI: 10.1093/annonc/mdq645] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
78 Groves MD. Leptomeningeal disease. Neurosurg Clin N Am. 2011;22:67-78, vii. [PMID: 21109151 DOI: 10.1016/j.nec.2010.08.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
79 Yap KK, Sutherland T, Liew E, Tartaglia CJ, Pang M, Trost N. Magnetic resonance features of primary central nervous system lymphoma in the immunocompetent patient: a pictorial essay. J Med Imaging Radiat Oncol 2012;56:179-86. [PMID: 22498191 DOI: 10.1111/j.1754-9485.2012.02345.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
80 Suzuki Y, Tanaka H, Suyama K, Mochida H, Suzuki Y. Secondary Central Nerve System Lymphoma With Intratumoral Hemorrhage Suggested as Intravascular Lymphoma by Autopsy: A Case Report. J Clin Med Res 2017;9:953-7. [PMID: 29038675 DOI: 10.14740/jocmr3177w] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
81 Aresu L, Agnoli C, Nicoletti A, Fanelli A, Martini V, Bertoni F, Marconato L. Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma. Front Vet Sci 2021;8:647009. [PMID: 33816589 DOI: 10.3389/fvets.2021.647009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 McClement AP, Healy GM, Redmond CE, Stocker E, Connaghan G, Skehan SJ, Killeen RP. Minimally Invasive Diagnosis of Secondary Intracranial Lymphoma. Case Rep Hematol 2016;2016:6165172. [PMID: 28018686 DOI: 10.1155/2016/6165172] [Reference Citation Analysis]
83 Mitra S, Mehta A, Gupta SK, Sharma A, Louis AR, Sharma MK, Saxena U, Simson DK, Dewan A. Primary Gastric Burkitt's Lymphoma. Rare Tumors 2014;6:5300. [PMID: 25568743 DOI: 10.4081/rt.2014.5300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011;32:984-92. [PMID: 20616176 DOI: 10.3174/ajnr.A2171] [Cited by in Crossref: 208] [Cited by in F6Publishing: 83] [Article Influence: 17.3] [Reference Citation Analysis]
85 Gatt ME, Grisaro S. Central nervous system prophylaxis in mantle cell lymphoma. Blood 2009;114:5402-3. [DOI: 10.1182/blood-2009-09-245027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
86 Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies. Clin Lymphoma Myeloma Leuk 2015;15:451-7. [PMID: 25816933 DOI: 10.1016/j.clml.2015.02.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
87 Khasraw M, Noy A, Gilbert M, Omuro A. Neurological Complications of Non-Hodgkin Lymphoma. In: Batchelor T, Deangelis LM, editors. Lymphoma and Leukemia of the Nervous System. New York: Springer; 2012. pp. 267-85. [DOI: 10.1007/978-1-4419-7668-0_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]